Shanghai Pharmaceuticals (SHPMF) Stock Price, News & Analysis

Company Overview

Shanghai Pharmaceuticals (OTCMKTS: SHPMF) is a leading integrated healthcare company headquartered in Shanghai, China. Established in 1994 through the consolidation of state‐owned pharmaceutical entities, the firm has built a comprehensive business model spanning pharmaceutical distribution, manufacturing and retail pharmacy services. The company’s core distribution network delivers prescription and over‐the‐counter medications, medical devices and healthcare products to hospitals, clinics and community pharmacies across mainland China.

In its manufacturing segment, Shanghai Pharmaceuticals produces active pharmaceutical ingredients (APIs), finished dosage forms and chemical intermediates. The company’s research and development arm focuses on both generic and innovative therapies, with a pipeline that addresses major therapeutic areas such as cardiovascular, oncology and central nervous system disorders. With multiple production sites certified to international quality standards, Shanghai Pharmaceuticals supports domestic demand and exports to select Asian and African markets under strategic partnerships.

On the retail side, the company operates a chain of community pharmacies under the “Shanghai Pharma” brand, providing healthcare advice, prescription fulfillment and wellness services to end users. Over the years, Shanghai Pharmaceuticals has pursued targeted acquisitions and alliances to strengthen its supply‐chain capabilities and broaden its product offering. Led by an experienced executive team and overseen by a board of directors with deep industry expertise, the company continues to expand its footprint in China’s healthcare sector and enhance its R&D and commercial platforms.

Key Stats

• Today's Range: $1.46 to $1.46
• 50-Day Range: $1.46 to $1.46
• 52-Week Range: $1.46 to $1.53
• Volume: N/A
• Average Volume: 33,943 shs
• Market Capitalization: N/A
• P/E Ratio: 1.57
• Dividend Yield: 18.04%
• Price Target: N/A
• Consensus Rating: N/A

Shanghai Pharmaceuticals Stock Analysis - MarketRank™

Shanghai Pharmaceuticals scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Shanghai Pharmaceuticals.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Shanghai Pharmaceuticals is 1.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.97.

Price to Earnings Ratio vs. Sector

The P/E ratio of Shanghai Pharmaceuticals is 1.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.13.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Shanghai Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Shanghai Pharmaceuticals has recently increased by 98.17%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Shanghai Pharmaceuticals pays a meaningful dividend of 2.01%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Shanghai Pharmaceuticals does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Shanghai Pharmaceuticals is 28.26%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: -0.08

News Sentiment

Shanghai Pharmaceuticals has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Shanghai Pharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Shanghai Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Institutions

6.84% of the stock of Shanghai Pharmaceuticals is held by institutions.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Distribution
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SHPMF
• CIK: 1570300
• Web: www.sphchina.com
• Phone: 86-21-6373-0908
• Fax: N/A
• Employees: 49,234
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 1.57
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A